CHAELIN KIM

[Finn McQuaid @CFMcQuaid]

Our framework that informed the @WHO TB & climate change policy brief out now in @LancetRespirMed, exploring the intersections and implications of climate change for the TB epidemic. Key message? TB should be considered a climate-sensitive disease
https://t.co/e8xNQtKSFj

[Finn McQuaid @CFMcQuaid]

When fluoroquinolone resistance status is unknown, empirical use of BPaLM (adding moxifloxacin to BPaL) is cost-effective as a replacement for BPaL even with high fluoroquinolone resistance levels!🦠💊
https://t.co/IB0iJz66xC

[Richard White @richardwhite321]

Are you interested in #TB and have experience in #modelling infectious diseases?

Come join us in the fun, supportive, and world-leading TB Modelling Group at @LSHTM !

We have a 1 year Research Fellow position (with possible extension)

Closing date of 30 May 2025 👉

https://t.co/943boPrITM

[Finn McQuaid @CFMcQuaid]

@emilyakendall @NickMenzies2 @richardwhite321 @ted_h_cohen @rycktessman @LSHTM @LSHTM_TB @cmmid_lshtm @lshtm_tbmod And the original work which this built on is now out too - projecting the health and economic effects of pan-TB (with the same fantastic group of researchers). Thank you to all involved! https://t.co/rWPcgzUSoM

[Finn McQuaid @CFMcQuaid]

Are pan-TB treatment regimens likely to drive the emergence of novel drug resistance? We investigated, in a new paper here https://t.co/XkFr0o1sMv with @emilyakendall @NickMenzies2 @richardwhite321 @ted_h_cohen @rycktessman @LSHTM @LSHTM_TB @cmmid_lshtm @lshtm_tbmod

[Richard White @richardwhite321]

Subclinical tuberculosis is ~half of prevalent TB, could make people sick and cause transmission

So, it is crucial to understand whether new TB vaccines prevent subclinical TB and what it means for global impact

Find out how more in our new paper in @LancetMicrobe

https://t.co/naw0OdU2au

[LSHTM AMR Centre @LSHTM_AMR]

@OazisHealth @TropMedOxford @GLGAMR @PaulTurnerMicro @senjutisaha @BakarySanyan9 @mrcunitgambia @CFMcQuaid of the @LSHTM_TB and @tb_mac is keen to develop decision support tools for TB treatment but is hampered by data on drug susceptibility testing as well as on AMR prevalence.

[Finn McQuaid @CFMcQuaid]

Great to see this thought piece out! For so many TB drugs DST is still not widely available - to support clinicians, policymakers must provide pragmatic treatment recommendations for situations where resistance profile is unknown. So what should they do?
https://t.co/wab2NrwPMd

[CHAELIN KIM @ckim0509]

This week in #KnightGroup, @NaomiMFuller has shared her, Alastair's, and @QuentinLclrc's experience at the recent🦠Epidemics conference in Italy🇮🇹! Interesting discussions on privilege in research and effective peer critique.💡🧐

[Richard White @richardwhite321]

Who knew a meet up of TB modellers could be so much fun!

Such a wonderful bunch of bright, open and friendly folks, dedicated to ending TB

I'd be willing to bet that some new collaborations were formed.

Thanks to BMGF for funding

#Unionconference
@tb_mac

[Steady Path @steady_path_]

스테디 엘라의 'ChatGPT를 활용한 대학원 생활 세미나' 설문조사를 진행하고 있습니다!📋

설문조사를 진행해주시면, 세미나 오픈 시 바로 신청서를 전달드리겠습니다🙌🏻

ChatGPT를 활용해서 대학원 생활하기 세미나가 뭔지 궁금하시다면 아래 링크로🔽
https://t.co/3m3lrPe4CA

[Steady Path @steady_path_]

빠른 구독 신청은 아래 링크에서 부탁드려요🙌🏻
https://t.co/7Awmn6fOrX
메일 주소만 기입하시면 신청 완료입니다!💌
달에 ✌🏻번, 15일과 30일에 받아보실 수 있습니다:)
많은 관심 부탁드립니다🫶🏻

[Steady Path @steady_path_]

https://t.co/MLy5lr3YYi
젤라(@ZJ_txt)님과 함께 해외 유학&취준기를 에세이형식의 레터로 발행 예정입니다.
레터 제목은 “엘라와 젤라, 유럽에서 살아남을 수 있을 것인가?🇬🇧🇳🇱”입니다.
구독하시면 10/30부터 받아보실 수 있습니다💌 구독 신청은 아래 링크에서 부탁드려요🫶🏻

[Gwen Knight @gmknght]

Very happy to say a big Croeso (welcome 🏴󠁧󠁢󠁷󠁬󠁳󠁿) and congrats to @ckim0509 who has started an MRCLID PhD with @CFMcQuaid and me @LSHTM. Looking forward to some interesting work on modelling empiric regimens for TB!

[Vaccine Centre @LSHTM_Vaccines]

A 🆕systematic review & meta-analysis of case-control studies provides important practical insights into effective #WASH components to control #TyphoidFever. 🫧🤲🚾

🔖👉https://t.co/MC6DTa6iHA

[International Vaccine Institute (IVI) @IVIHeadquarters]

New #AMR research in @GlobalHealthBMJ makes a case for increasing coverage of existing vaccines and developing new vaccines as an effectives means of reducing the spread of antimicrobial resistance ⤵️

https://t.co/rGtknMOz13 @WHO @LSHTM

[BMJ Global Health @GlobalHealthBMJ]

"Increased coverage of existing vaccines and development of new vaccines are effective means to reduce AMR, and this evidence should inform the full value of vaccine assessments." @IsabelFrost19

📣 New Research ➡️ https://t.co/DfU14KZSPD

[LSHTM AMR Centre @LSHTM_AMR]

Over half a million #AMR-associated deaths could be preventable using vaccines, shows new research in @GlobalHealthBMJ 💉

The team from @IVIHeadquarters, @WHO & @LSHTM say their predictions support the need for vaccine scale-up and development 👉 https://t.co/xs5WrTGKqW

[PPAFoundation @PPAFoundation]

Our interns & volunteers help overcome poverty issues of families. Improved cooking in Haiti is a focus. #GiveLocalWP